TrialSignal
Clinical trial intelligence report
A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06433557
Status
ACTIVE_NOT_RECRUITING
Phase
PHASE2
Sponsor
Ascendis Pharma Growth Disorders A/S
Executive brief
Investment-Ready Snapshot
This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06433557
Indication
Achondroplasia
Modality
combination therapy
Target
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Intervention
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.